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in 27 patients (111 lesions). The mean stent length per patient was 87.4±45.2mm. At 30
days the cumulative MACE rates were 10.3%: 7.1% patients developed a non–Q, 1.9% a
Q-wave MI, 0.6% died for non-cardiac reasons and 0.6% had a repeat revascularization.
Clinical follow-up was obtained in all eligible 112 patients treated on 359 lesions at a
mean time of 6.5±2.2 months. The cumulative MACE rate was: 3 deaths (2.7%, 1 for car-
diac reasons) and 4 (3.6%) MI. Target lesion revascularization (TLR) was performed in
24 (6.7%) lesions in 16 patients (14.3%). Target vessel revascularization was required in
18 (16.1%) patients due to TLR of lesions treated with SES or to disease progression
(1.8% of patients). Cumulative total MACE rate was 22.3%. Cox regression analysis
revealed total stent length per patient as the most powerful independent predictor of
MACE. Overall stent thrombosis occurred in 3 (1.9%) patients.
CONCLUSION
Multivessel SES implantation can be safely performed on patients with complex coronary
artery disease. The need for revascularization increases due to cumulative effect of TLR
on patients with multiple lesions.
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Objective: To evaluate predictors of periprocedural creatine kinase MB isoenzyme (CK-
MB) elevation following implantation of sirolimus-eluting stents (SES).
Methods: We studied 320 consecutive patients who underwent SES implantation in 722
coronary lesions between April 2002 and January 2003. Univariate and multivariate
logistic regression analyses were used to determine independent predictors of CK-MB
elevation from clinical, angiographic and procedural covariates.
Results: CK-MB elevation > 3 times upper limit of normal occurred in 42 patients
(13.1%). Those patients less frequently received elective glycoprotein IIb/IIIa agents (GP
IIb/IIIa) (19% vs. 43%, P=0.001) and had longer SES implanted (total stent length per
patient 86 vs. 59mm, P=0.001). Univariate predictors of CK-MB elevation were: multives-
sel disease, OR 2.05 (95%CI 1.05-3.99, P=0.032); number of treated lesions, OR 1.43
(95%CI 1.17-1.76, P=0.001); de-novo lesion, OR 1.80 (95%CI 1.02-3.18, P=0.034); total
stent length per patient, OR 1.13 (95%CI 1.01-1.20, P=0.001) and elective use of GP IIb/
IIIa, OR 0.31 (95%CI 0.14-0.70, P=0.003). Multivariate analysis indicated that total stent
length per patient (OR 1.02 (95%CI 1.01-1.03, P=0.001, predisposing factor) and elective
use of GP IIb/IIIa (OR 0.21 (95%CI 0.08-0.50, P=0.001, protective factor) were indepen-
dent predictors of CK-MB elevation. At 30 days and 9.5 months follow-up patients with
and without periprocedural myonecrosis had similar composite MACE (death/myocardial
infarction/repeat revascularization, 2.4% vs. 1.4%, P=0.65 and 21.4% vs. 16.9%, P=0.47,
respectively).
Conclusion: In patients treated with SES, CK-MB elevation correlates with implantation
of longer stents, while elective use of GP IIb/IIIa lowers that risk.
1044-62 Post-Market Surveillance of the CYPHER Sirolimus-
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United States
Stanley Katz, Marco A. Costa, Emerson C. Perin, Stephen R. Ramee, Peter B. Berger, 
Peter Block, Northshore Hospital, Manhasset, NY
Background: e-CYPHER is a global, internet-based registry collecting data on the use
of the CYPHER™ Sirolimus-eluting Stent (CYPHER) in routine clinical practice. In the
US, e-CYPHER is the database tool for the FDA-mandated post market surveillance
requirement.
Methods: The US post market surveillance includes 2000 patients at up to 75 centers.
Data are recorded in the e-CYPHER registry from consecutive patients treated with at
least one CYPHER stent, with clinical follow-up at 1, 6 and 12 months. Demographic,
treatment, and adverse event information are collected. Events reported from US
patients are adjudicated by an independent clinical events committee.
Results: Enrollment into the US registry began on August 6, 2003. Currently, 110
patients have been enrolled at 6 sites. One month data from the US will be available at
the time of presentation. Site reported one month event rates from 3330 patients treated
at sites throughout Europe, Latin America, Asia Pacific and Middle East are presented
below. 
Conclusions: The e-CYPHER registry is the largest ongoing registry of drug-eluting 
stent usage, and will provide ongoing safety information for the CYPHER stent.
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1062-41 The Impact of Renal Insufficiency on Long-Term 
Survival of Patients With Diabetes Undergoing 
Percutaneous Coronary Intervention
Jeffrey S. Berger, Timothy A. Sanborn, Warren Sherman, David L. Brown, Beth Israel 
Medical Center, New York, NY
Introduction: Diabetes and renal insufficiency are each associated with an increased
risk of mortality among patients with coronary artery disease (CAD). However, the impact
of coexistent renal disease and diabetes in patients with established CAD is not well
understood. We sought to evaluate the impact of renal insufficiency on survival of
patients with diabetes and CAD. Methods: Three hospitals in New York City contributed
data on 1142 consecutive diabetic patients undergoing percutaneous coronary interven-
tion (PCI) in 1998-9. Renal disease was defined by a creatinine > 2.5mg/dl and included
patients on chronic dialysis. The primary end-point was all-cause mortality at 3-year fol-
low-up. Results: Among diabetics, renal disease was present in 75 patients (6.6%).
There was no difference in age, race, or gender between groups. Diabetics with renal dis-
ease were more commonly obese (41.3% vs. 30.7%, P=0.079) and less likely to be
smokers (1.3% vs. 9.4%, P=0.018). Hypertension and stroke were not different between
groups. Patients with renal disease had a greater prevalence of vascular disease (25.3%
vs. 9.7%, P<0.001), prior heart failure (22.7% vs. 7.7%, P<0.001) and previous cardiac
surgery (33.3% vs. 21.6%, P=0.019). Diabetics with renal disease presented more often
with 3-vessel CAD (36% vs. 23%, P=0.009). Mean ejection fraction was lower in diabet-
ics with renal disease (46% vs. 50%, P<0.001). Angiographic success was 97% in both
groups. In-hospital mortality was significantly greater among diabetics with renal disease
than diabetics without renal impairment (6.7% vs. 0.6%, P<0.001). At 3-year follow-up,
mortality for diabetics with renal disease was 44% vs. 11% in diabetics without renal
impairment (log-rank P<0.0001). On Cox proportional hazards analysis, renal disease
among diabetics was an independent predictor of mortality (Hazard Ratio, 3.067, 95%
Confidence Interval, 1.987-4.733, P<0.001). Conclusion: Renal disease in diabetics
with CAD is independently associated with a 3-fold increase in the hazard of death. The
increased mortality of CAD diabetics with renal impairment should stimulate further
research concerning appropriate treatment and surveillance regimens.
1062-42 Adverse Events in Patients With Normal Renal Function 
Are Increased With Modest Increases in Creatinine 
Clearance After Percutaneous Coronary Intervention
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Beaumont Hospital, Royal Oak, MI
Background: Creatinine clearance (CrCl) reduction after percutaneous coronary inter-
vention (PCI) is associated with increases in adverse events in patients with chronic kid-
ney disease. However, the impact of CrCl changes after PCI in patients with normal
baseline renal function is not well defined.
Methods: Data was prospectively collected from 1993 to 2003 on 20,479 patients under
going PCI. Patients were excluded for an estimated baseline CrCl <90 ml/min, prior his-
tory of renal failure or dialysis, coronary artery bypass surgery, ejection fraction <30%,
shock, no reflow, and residual stenosis >50%. Patients were grouped by CrCl reduction
for comparison. Multivariate analysis was used to determine the impact on in-hospital
adverse events.
Results: The incidence of a > 25% CrCl reduction after PCI in patients with previously
normal renal function was 0.08% (262/3658). Independent predictors with an odds ratio
>2 were: male gender (P value<0.001), intra-aortic balloon pump use (P value=0.01),
and age over 70 (P value=0.0004). Patients with a decrease in CrCl had increased
events as shown below. 
One Month Event Rates
(3330 patients)
MACE (%) 1.80
Death (%) 0.66
MI (%) 0.69
TLR (%) 0.24
CABG (%) 0.21
SAT (%) 0.87
Adverse Events with Decreasing Creatinine Clearance 
Creatinine Clearance Decrease
Adverse Events 0-25% > 25-<50% >50% P value
N=3396 N=231 N=31
Death 0.3% 0.9% 13.0% <0.0001
Bleeding 0.7% 1.3% 16.0% <0.0001
Hospitalization >4days 12% 30% 56% <0.0001
Myocardial Infarction 0.5% 0.4% 3.2% 0.16
Reoccclusion 0.4% 0.4% 0.0% 0.62
